000 01606 a2200457 4500
005 20250511183630.0
264 0 _c19921210
008 199212s 0 0 eng d
022 _a0009-9104
024 7 _a10.1111/j.1365-2249.1992.tb07926.x
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aSchreck, R
245 0 0 _aSelection of a muramyl peptide based on its lack of activation of nuclear factor-kappa B as a potential adjuvant for AIDS vaccines.
_h[electronic resource]
260 _bClinical and experimental immunology
_cNov 1992
300 _a188-93 p.
_bdigital
500 _aPublication Type: Journal Article
650 0 4 _aAcetylmuramyl-Alanyl-Isoglutamine
_xchemistry
650 0 4 _aAcquired Immunodeficiency Syndrome
_xtherapy
650 0 4 _aAdjuvants, Immunologic
650 0 4 _aAnimals
650 0 4 _aAntioxidants
_xpharmacology
650 0 4 _aBase Sequence
650 0 4 _aCell Line
650 0 4 _aGene Expression
650 0 4 _aHumans
650 0 4 _aIn Vitro Techniques
650 0 4 _aInterleukin-8
_xgenetics
650 0 4 _aMice
650 0 4 _aMolecular Sequence Data
650 0 4 _aNF-kappa B
_xmetabolism
650 0 4 _aOligodeoxyribonucleotides
_xchemistry
650 0 4 _aReactive Oxygen Species
_xmetabolism
650 0 4 _aStructure-Activity Relationship
700 1 _aBevec, D
700 1 _aDukor, P
700 1 _aBaeuerle, P A
700 1 _aChedid, L
700 1 _aBahr, G M
773 0 _tClinical and experimental immunology
_gvol. 90
_gno. 2
_gp. 188-93
856 4 0 _uhttps://doi.org/10.1111/j.1365-2249.1992.tb07926.x
_zAvailable from publisher's website
999 _c1430763
_d1430763